Varian sees slight revenue increase in 2015

AuntMinnie.com staff writers
Jan 6, 2016

Radiation therapy firm Varian Medical Systems has posted financial results for its 2015 fiscal year.

The company's total revenues for fiscal 2015 were $3.1 billion, an increase of 2% compared to $3 billion in 2014. Net earnings were $412 million, also an increase of 2% compared to 2014's $403.7 million.

Varian's oncology system revenues were flat in fiscal 2015, and its imaging component revenues decreased 7%. The company attributed these results in part to unfavorable foreign currency exchange rates.

Latest in Radiation Oncology/Therapy
Chat Gpt Artificial Intelligence Ai Head
ChatGPT-4 not reliable in cancer patient messaging
April 25, 2024
Theranostics with Thomas Hope, MD, University of California, San Francisco (UCSF)
The rise of theranostics: Part 2 -- Moving into communities
April 4, 2024
Team members from the theranostics clinic under University of Texas Health Science Center at San Antonio's Department of Radiology show one aspect of a Pluvicto infusion treatment. The L block lead shield over the syringe helps protect certified nuclear medicine technologist James Johnson (left), and nuclear radiologist Penny Vroman, MD (right), from radiation emitted by the drug. (Photo courtesy of UT Health San Antonio Department of Radiology)
The rise of theranostics: Part 1 -- Gaining momentum
March 26, 2024
Screenshot (1076)
Researcher outlines radiation oncology workforce challenges
February 23, 2024
Related Stories
2015 10 07 10 09 21 574 Bolus 200
Radiation Oncology/Therapy
3D printing helps shape radiation therapy to patients
2014 10 16 15 12 34 847 Wallner Paul 200
Radiation Oncology/Therapy
Payment parity in radiation therapy best serves cancer patients
2014 09 24 14 22 51 331 Curry Heather 175
Radiation Oncology/Therapy
Choosing Wisely boosts use of short-course breast radiation therapy
2014 05 28 16 41 19 81 Golden Gate San Francisco 200
Radiation Oncology/Therapy
ASTRO: Radiation therapy cost analysis suggests inefficiency
More in Radiation Oncology/Therapy
ChatGPT-4 not reliable in cancer patient messaging
By Amerigo Allegretto
ChatGPT-4 is not a reliable source for answering patients’ questions regarding cancer and needs physician monitoring.
April 25, 2024
Chat Gpt Artificial Intelligence Ai Head
The rise of theranostics: Part 2 -- Moving into communities
By Liz Carey
In part 2 of The Rise of theranostics series, experts weigh in on getting started in prostate cancer theranostics as some private urology, radiation oncology practices, and radiologist groups begin building their abilities.
April 4, 2024
Theranostics with Thomas Hope, MD, University of California, San Francisco (UCSF)
The rise of theranostics: Part 1 -- Gaining momentum
By Liz Carey
FDA-approved radiopharmaceuticals have energized the field of theranostics. In part 1 of a series, experienced theranostics leaders offer implications of the latest clinical trials, how a theranostics clinic works, and advice for introducing theranostics.
March 26, 2024
Team members from the theranostics clinic under University of Texas Health Science Center at San Antonio's Department of Radiology show one aspect of a Pluvicto infusion treatment. The L block lead shield over the syringe helps protect certified nuclear medicine technologist James Johnson (left), and nuclear radiologist Penny Vroman, MD (right), from radiation emitted by the drug. (Photo courtesy of UT Health San Antonio Department of Radiology)
Researcher outlines radiation oncology workforce challenges
By Amerigo Allegretto
Arya Amini, MD, spoke with AuntMinnie.com about a paper he co-authored that outlines workforce challenges being faced by radiation oncologists.
February 23, 2024
Screenshot (1076)
PET/CT radiomics predicts outcomes in women with cervical cancer
By Will Morton
A radiomics nomogram based on F-18 FDG-PET/CT imaging could help clinicians assess long-term outcomes in women undergoing treatment for locally advanced cervical cancer.
February 2, 2024
Representative example of tumor segmentation of radiomics regions of interest (ROI) on axial, coronal, and sagittal PET/CT imaging.
PSMA-PET helps plan treatment in men with relapsed prostate cancer
By Will Morton
PSMA-PET led to management changes in one-third of men receiving salvage radiotherapy for prostate cancer that recurred after radical prostatectomy.
January 31, 2024
Prostate Cancer
FAPI-PET shows promise in head and neck cancer patients
By Will Morton
In a comparative imaging trial, FAPI-PET/CT outperformed FDG-PET/CT in detecting primary tumors in patients with head and neck cancer.
January 26, 2024
PET/CT and MR images of a 72-year-old woman. (A) F-18 FDG-PET images (left and top) and PET/CT images (bottom) shown in coronal, sagittal, and axial views (from left to right), demonstrated a metastatic lymph node of the right neck with intensive metabolic activity (black arrow, SUVmax, 30.1) but presented no evidence for primary tumor. (B) Ga-68 FAPI-PET images (top and right) and PET/CT images (bottom), shown in axial, sagittal, and coronal views (from left to right), also detected metastatic lymph node with high Ga-68 FAPI tracer activity (black arrow, SUVmax, 16.3). There was intensive uptake of Ga-68 FAPI in palate (red arrow, SUVmax, 11.3). (C) T1-weighted, T2-weighted, and contrast-enhanced T1-weighted MRI also presented no evidence for primary tumor. Subsequent surgery confirmed mucoepidermoid carcinoma of palate. Image courtesy of the Journal of Nuclear Medicine.
TerraPower distributes first shipments of Ac-225
By AuntMinnie.com staff writers
TerraPower Isotopes has shipped its first samples of Actinium-225 (Ac-225) to two pharmaceutical companies to develop targeted cancer treatments in drug trials.
January 24, 2024
Isotopes1
FAPI-PET outperforms FDG-PET in diagnosing pancreatic cancer
By Will Morton
F-18 FAPI-PET/CT is superior to F-18 FDG-PET/CT for diagnosing and staging patients with pancreatic cancer.
January 5, 2024
Typical PET (top), PET/CT (middle), and CT and MR (bottom) images of primary tumor obtained using both radiotracers in representative patients (A and B). Tumor is marked by arrows. DWI = diffusion-weighted imaging. Image courtesy of the Journal of Nuclear Medicine.
PET/CT scans ‘crucial’ in patients with NK/T-cell lymphoma
By Will Morton
PET/CT has significant advantages over conventional methods for lesion detection and staging in patients with natural killer/T-cell lymphoma.
December 22, 2023
A 50-year-old man with recently diagnosed nasal-type NK/T-cell lymphoma underwent an F-18 FDG-PET/CT scan (A–D) for initial staging. Maximum-intensity-projection image (A) shows hypermetabolic lesions in both ethmoid sinus (thin arrow), both cervical lymphatic chains (arrowhead), left upper lung (thick arrow), liver, and spleen. Transaxial images show an F-18 FDG-avid mass in both ethmoid sinus (B). The scan shows intense F-18 FDG radiotracer uptake in left upper lung and uptake in the liver and spleen (CT showed no lesions), suggesting malignancy (C–D). Finally, after the PET/CT scan was done, the patient’s staging was changed from II to IV.
FES-PET better than FDG-PET in breast cancer patients
By Will Morton
In a head-to-head comparison, F-18 fluoroestradiol (FES)-PET/CT was better than standard FDG-PET/CT for the initial staging of estrogen receptor-positive breast cancer patients.
December 21, 2023
Axial PET (a) and axial fusion (b) images of F-18 FES (top) and F-18 FDG (bottom) with concordant uptake of both radiotracers in a left breast mass and left axillary node metastasis in correlation with CT imaging (c). Image courtesy of the European Journal of Hybrid Imaging.
NorthStar to end production of Mo-99
By Will Morton
NorthStar Medical Radioisotopes will shut down its molybdenum-99 (Mo-99) production facilities in Beloit, WI, by the end of 2023.
October 9, 2023
Isotopes
Page 1 of 461
Next Page